Ocugen licenses OCU400 retinitis pigmentosa gene therapy rights to Roots Pharmaceutical in MENA region

By Public Technologies
  • Ocugen signed an exclusive MENA licensing deal with Roots Pharmaceutical for OCU400, its modifier gene therapy for retinitis pigmentosa.
  • Terms include an upfront license fee, up to $4 million in initial development payments, up to $255 million in sales milestones.
  • Ocugen will earn 22% royalties on OCU400 net sales in the region.
  • Commercial supply will be manufactured and supplied by Ocugen under a related supply agreement.
  • Phase 3 liMeliGhT topline data is expected in Q1 2027, ahead of planned U.S. and European filings.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ocugen Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610140630PRIMZONEFULLFEED9845309) on October 14, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.